Side-by-side · Research reference

BPC-157vsSelank

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BHuman-MechanisticDraft11/40 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

01Mechanism of Action

Parameter

BPC-157

Selank

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Feedback intact?

No known endogenous receptor; mechanism still under investigation

No GABA-receptor binding; no dependence reportedMedvedev 2007

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Selank

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

150–300 mcg / dose intranasalZaderej 2014

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

2–3× per day during stress

Lower / starter dose

200 mcg / day

Conservative starter for new users.

75 mcg / dose

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Human-mechanistic + Russian clinical trialsMedvedev 2007

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

10–14 day cycles, repeated as needed

Reconstitution

Bacteriostatic water, 1–2 mL

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Morning + early afternoon preferred

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

Short (minutes plasma); CNS effect lasts ~3 hr

04Side Effects & Safety

Parameter

BPC-157

Selank

Injection site reaction

Mild irritation (anecdotal)

—

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid — insufficient data

Long-term safety

Unknown beyond Phase 2 trial duration

Limited Western RCT data

Drug interactions

None established

—

Nasal irritation

—

Mild burning or congestion (transient)

Sedation

—

None — distinct from benzodiazepinesMedvedev 2007

Dependence / withdrawal

—

None reported in clinical useZaderej 2014

Cognitive impairment

—

None — opposite effect (enhancement)

Allergic reaction

—

Rare hypersensitivity

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Selank

·Active autoimmune disease (theoretical via immunomodulation)

05Administration Protocol

Parameter

BPC-157

Selank

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Refrigerate after reconstitution; ≤30 days. Light-protected.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

Avoid co-administration with strong sedatives or other anxiolytics initially.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Selank

— no documented stacks